Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Launched by BO LU · May 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of combined treatments—specifically, radiation therapy and immunotherapy—on lung cancer patients. The goal is to understand how these treatments might affect heart and lung health. Researchers will closely monitor patients over time, collecting blood samples to find markers that could help predict any heart or lung-related issues that might arise during treatment.

To participate in this study, patients need to be at least 18 years old and have been diagnosed with a type of lung cancer that is locally advanced. They must be planning to receive curative radiation therapy (with a specific dose) along with immunotherapy, although they can’t be receiving chemotherapy at the same time. Participants can expect regular monitoring and blood tests throughout the study, which aims to provide valuable insights into the safety of these treatment combinations. It’s important to note that patients who have had previous radiation therapy to the chest or have certain severe health conditions may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient older than 18 years age
• • Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
• • Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
• • Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
• • ECOG performance status of 0-2
• • Life expectancy of 6 months or longer
• • Patient able to provide a written informed consent prior to study entry
• Exclusion Criteria:
• • Prior thoracic radiotherapy to chest.
• • Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
• • Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.